Combine and conquer: Challenges for targeted therapy combinations in early phase trials

Nature Reviews Clinical Oncology

Volumn 14, Issue 1, 2017, Pages 57-66

  Lopez, Juanita S ^a   Banerji, Udai ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BORTEZOMIB; COBIMETINIB; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FASUDIL; GEFITINIB; IPILIMUMAB; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NIVOLUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; RITUXIMAB; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SOMATOMEDIN RECEPTOR; TRAMETINIB; TRANSCRIPTION FACTOR GATA 2; VEMURAFENIB; ANTINEOPLASTIC AGENT;

BRAF GENE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CLONAL EVOLUTION; DERMATITIS; DIARRHEA; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SAFETY; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HEALTH CARE PLANNING; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; IMMUNE SYSTEM; KERATOACANTHOMA; LETHALITY; LUNG TUMOR; MELANOMA; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NAUSEA; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN TARGETING; RASH; REVIEW; RNA ANALYSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN CARCINOMA; STOMATITIS; SYSTEMS BIOLOGY; TREATMENT INDICATION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATIENT SELECTION; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNE SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATIENT SELECTION; SYSTEMS BIOLOGY; TUMOR MICROENVIRONMENT;

EID: 84977125861     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.96     Document Type: Review

References (119)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
2. Westin, J. R. & Kurzrock, R. It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol. Cancer Ther. 11, 2549-2555 (2012).
3. Molife, L. R. et al. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors. Clin. Cancer Res. 20, 6284-6294 (2014).
4. Yap, T. A., Bjerke, L., Clarke, P. A. & Workman, P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Current Opin. Pharmacol. 23, 98-107 (2015).
5. Ellis, L. M. & Hicklin, D. J. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res. 15, 7471-7478 (2009).
6. Basu, B., Olmos, D. & de Bono, J. S. Targeting IGF-1R: Throwing out the baby with the bathwater? Br. J. Cancer 104, 1-3 (2011).
7. Grisham, R. N. et al. Extreme outlier analysis identifies occult mitogen-Activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer. J. Clin. Oncol. 33, 4099-4105 (2015).
8. Al-Ahmadie, H.et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov. 4, 1014-1021 (2014).
9. Mounier, N. et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-Associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101, 4279-4284 (2003).
10. Coiffier, B. E. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
11. Johnston, S. R. Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: cotargeting signaling pathways. J. Natl Cancer Inst. 107, djv212 (2015).
12. Jamal-Hanjani, M., Quezada, S. A., Larkin, J. & Swanton, C. Translational implications of tumor heterogeneity. Clin. Cancer Res. 21, 1258-1266 (2015).
13. Schmitt, M. W., Loeb, L. A. & Salk, J. J. The influence of subclonal resistance mutations on targeted cancer therapy. Nat. Rev. Clin. Oncol. 13, 335-347 (2016).
14. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 13, 714-726 (2013).
15. Gillies, R. J., Verduzco, D. & Gatenby, R. A. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer 12, 487-493 (2012).
16. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
17. Stewart, E. L., Tan, S. Z., Liu, G. & Tsao, M. S. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-A review. Transl. Lung Cancer Res. 4, 67-81 (2015).
18. Lito, P. N., Rosen, N. & Solit, D. B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19, 1401-1409 (2013).
19. Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94-109 (2014).
20. Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80-93 (2014).
21. Romano, E. et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin. Cancer Res. 19, 5749-5757 (2013).
22. Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877-1888 (2014).
23. Long, G. V., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444-451 (2015).
24. Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30-39 (2015).
25. Tolcher, A. et al. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin. Cancer Res. 21, 739-748 (2015).
26. Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679-692 (2012).
27. Keith, C. T., Borisy, A. A. & Stockwell, B. R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4, 71-78 (2005).
28. Lee, M. S. et al. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res. 67, 11359-11367 (2007).
29. Zhao, S. et al. Systems pharmacology of adverse event mitigation by drug combinations. Sci. Transl. Med. 5, 206ra140 (2013).
30. Lee, J. A. et al. Novel phenotypic outcomes identified for a public collection of approved drugs from a publicly accessible panel of assays. PLoS ONE 10, e0130796 (2015).
31. Herrera-Abreu, M. T. et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 3, 1058-1071 (2013).
32. McLornan, D. P., List, A. & Mufti, G. J. Applying synthetic lethality for the selective targeting of cancer. N. Engl. J. Med. 371, 1725-1735 (2014).
33. Steckel, M. et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 22, 1227-1245 (2012).
34. Pourdehnad, M. et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc. Natl Acad. Sci. USA 110, 11988-11993 (2013).
35. Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642-655 (2012).
36. Richardson, P. G., Mitsiades, C., T. Hideshima, T. & Anderson, K. C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. 57, 33-47 (2006).
37. Whitehurst, A. W. et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819 (2007).
38. O'Grady, M., Raha, D., Hanson, B. J., Bunting, M. & Hanson, G. T. Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer. BMC Cancer 5, 125 (2005).
39. Held, M. A. et al. Genotype-selective combination therapies for melanoma identified by high-Throughput drug screening. Cancer Discov. 3, 52-67 (2013).
40. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
41. Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract 3534]. J. Clin. Oncol. 28 (Suppl.), 15s (2010).
42. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
43. Robin Van Geel, E. E. et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer [abstract 3514]. J. Clin. Oncol. 32 (Suppl.), 5s (2014).
44. Atreya, C.E. et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) [abstract]. J. Clin. Oncol. 33 (Suppl.), 103 (2015).
45. Rona, D. et al. Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer [abstract]. J. Clin. Oncol. 33 (Suppl. 3), 611 (2015).
46. Mohr, S. E. et al. RNAi screening comes of age: improved techniques and complementary approaches. Nat. Rev. Mol. Cell Biol. 15, 591-600 (2014).
47. Taylor, J. & Woodcock, S. A. Perspective on the future of high-Throughput RNAi screening: will CRISPR cut out the competition or can RNAi help guide the way? J. Biomol. Screen. 20, 1040-1051 (2015).
48. Shi, J. et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat. Biotechnol. 33, 661-667 (2015).
49. Mutation Consequences and Pathway Analysis working group of the International Cancer Genome Consortium. Pathway and network analysis of cancer genomes. Nat. Methods 12, 615-621 (2015).
50. Nelander, S. et al. Models from experiments: combinatorial drug perturbations of cancer cells. Mol. Syst. Biol. 4, 216 (2008).
51. Iadevaia, S. et al. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res. 70, 6704-6714 (2010).
52. Mitsopoulos, C., Schierz, A. C., Workman, P. & Al-Lazikani, B. Distinctive behaviors of druggable proteins in cellular networks. PLoS Comput. Biol. 11, e1004597 (2015).
53. Kwong, L. N. et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med. 18, 1503-1510 (2012).
54. Kwong, L. N., Heffernan, T. P. & Chin, L. A systems biology approach to personalizing therapeutic combinations. Cancer Discov. 3, 1339-1344 (2013).
55. Ryall, K. A. & Tan, A. C. Systems biology approaches for advancing the discovery of effective drug combinations. J. Cheminform. 7, 7 (2015).
56. Korkut, A. et al. Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. eLife 4, e04640 (2015).
57. Stuhlmiller, T. J. et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 11, 390-404 (2015).
58. Domcke, S. et al. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).
59. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
60. Cassidy, J. W., Caldas, C. & Bruna, A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 75, 2963-2968 (2015).
61. Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338-350 (2012).
62. Gandara, D. R., Lara, P. N. Jr & Mack, P. C. Patient-derived xenografts for investigation of acquired resistance in oncogene-driven cancers: building a better mousetrap. J. Clin. Oncol. 33, 2839-2840 (2015).
63. Tricker, E. M. et al. Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov. 5, 960-971 (2015).
64. Gao, H. et al. High-Throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318-1325 (2015).
65. Park, S. R., Davis, M., Doroshow, J. H. & Kummar, S. Safety and feasibility of targeted agent combinations in solid tumours. Nat. Rev. Clin. Oncol. 10, 154-168 (2013).
66. Grob, J. J. et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 16, 1389-1398 (2015).
67. Ribas, A. et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: A phase 1b study. Lancet Oncol. 15, 954-965 (2014).
68. Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867-1876 (2014).
69. Soria, J. C., Massard, C. & Izzedine, H. From theoretical synergy to clinical supra-Additive toxicity. J. Clin. Oncol. 27, 1359-1361 (2009).
70. Blomme, E. A. & Will, Y. Toxicology strategies for drug discovery: present and future. Chem. Res. Toxicol. 29, 473-473 (2016).
71. Shimizu, T. et al. The clinical effect of the dual-Targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 18, 2316-2325 (2012).
72. Britten, C. D. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother. Pharmacol. 71, 1395-1409 (2013).
73. Bedard, P. L. et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin. Cancer Res. 21, 730-738 (2015).
74. Stewart, A., Thavasu, P., de Bono, J. S. & Banerji, U. Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors. Ann. Oncol. 26, 1504-1510 (2015).
75. Ho, H. K., Chan, J. C., Hardy, K. D. & Chan, E. C. Mechanism-based inactivation of CYP450 enzymes: A case study of lapatinib. Drug Metab. Rev. 47, 21-28 (2015).
76. de Jonge, M. J. et al. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest. New Drugs 31, 751-759 (2013).
77. Reardon, D. A. et al. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin. Cancer Res. 19, 900-908 (2013).
78. Whitesell, L. et al. HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Proc. Natl Acad. Sci. USA 111, 18297-18302 (2014).
79. Smyth, T. et al. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol. Cancer Ther. 13, 2793-2804 (2014).
80. Lindquist, S. Protein folding sculpting evolutionary change. Cold Spring Harb. Symp. Quant. Biol. 74, 103-108 (2009).
81. Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724-734 (2015).
82. Gianni, L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25-32 (2012).
83. Deuker, M. M., Marsh Durban, V., Phillips, W. A. & McMahon, M. PI3′-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov. 5, 143-153 (2015).
84. Zhao, Y. & Adjei, A. A. The clinical development of MEK inhibitors. Nat. Rev. Clin. Oncol. 11, 385-400 (2014).
85. Schmitt, M. A., Loeb, L. A. & Salk, J. J. The influence of subclonal resistance mutations on targeted cancer therapy. Nat. Rev. Clin. Oncol. 13, 335-0347 (2016).
86. Gandhi, L. et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J. Clin. Oncol. 32, 68-75 (2014).
87. Gadgeel, S. M. et al. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother. Pharmacol. 72, 1089-1096 (2013).
88. André, F., et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15, 580-591 (2014).
89. O'Brien, N. A. et al. Targeting PI3K/mTOR overcomes resistance to HER2-Targeted therapy independent of feedback activation of AKT. Clin. Cancer Res. 20, 3507-3520 (2014).
90. Yates, L. R. & Campbell, P. J. Evolution of the cancer genome. Nat. Rev. Genetics 13, 795-806 (2012).
91. Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338-345 (2013).
92. Fisher, R. & Larkin, J. Vemurafenib: A new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag. Res. 4, 243-252 (2012).
93. Rosell, R., Bivona, T. G. & Karachaliou, N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382, 720-731 (2013).
94. Advani, P. P., Crozier, J. A. & Perez, E. A. HER2 testing and its predictive utility in anti-HER2 breast cancer therapy. Biomark. Med. 9, 35-49 (2015).
95. Ashraf, N., Kothari, N. & Kim, R. Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing. J. Natl Compr. Canc. Netw. 12, 1433-1442 (2014).
96. Perkins, G. et al. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. Pharmacogenomics 15, 1043-1052 (2014).
97. Therkildsen, C. et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-Analysis. Acta Oncol. 53, 852-864 (2014).
98. Poulikakos, P. I. & Rosen, N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19, 11-15 (2011).
99. Tolcher, A. W. et al. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother. Pharmacol. 75, 183-189 (2015).
100. Hidalgo, M. et al. Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 4, 998-1013 (2014).
101. Robles, A. I. & Varticovski, L. Harnessing genetically engineered mouse models for preclinical testing. Chem. Biol. Interact. 171, 159-164 (2008).
102. Celina, G. G. et al. MEK plus PI3K/mTORC1/2 therapeutic efficacy is impacted by TP53 mutation in preclinical models of colorectal cancer. Clin. Cancer Res. 21, 5499-5510 (2015).
103. Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251 (2012).
104. Apetoh, L. et al. Combining immunotherapy and anticancer agents: The right path to achieve cancer cure? Ann. Oncol. 26, 1813-1823 (2015).
105. Zamarin, D. & Postow, M. A. Immune checkpoint modulation: rational design of combination strategies. Pharmacol. Therapeutics 150, 23-32 (2015).
106. Vinay, D. S. et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 35, S185-S198 (2015).
107. Ribas, A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5, 915-919 (2015).
108. Teng, M. W., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75, 2139-2145 (2015).
109. Das, R. et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194, 950-959 (2015).
110. Fridman, W. H., Pages, F. & Sautes-Fridman, C. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
111. Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202-216 (2016).
112. Balachandran, V. P. et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 17, 1094-1100 (2011).
113. Zitvogel, L. et al. Immunological off-Target effects of imatinib. Nat. Rev. Clin. Oncol. http://dx.doi.org/10.1038/nrclinonc.2016.41 (2016).
114. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01738139 (2016).
115. Ribas, A. et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366 (2013).
116. Johnson, D. B. et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol. Res. 1, 373-377 (2013).
117. Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012).
118. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
119. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012).